Data Portal @ linkeddatafragments.org

Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Cambridge_Antibody_Technology> ?p ?o. }

• Cambridge_Antibody_Technology abstract "Cambridge Antibody Technology (officially Cambridge Antibody Technology Group Plc, informally CAT) was a biotechnology company headquartered in Cambridge, England, United Kingdom. Its core focus was on antibody therapeutics, primarily using phage display and ribosome display technology.Technology developed by CAT was used to create adalimumab, the first fully human antibody blockbuster drug. Humira, the brand name of adalimumab, is an anti-TNF antibody discovered by CAT as D2E7, then developed in the clinic and marketed by Abbott Laboratories. The company was also behind belimumab, the anti-BlyS antibody drug marketed as Benlysta and the first new approved drug for systemic lupus in more than 50 years.Founded in 1989, CAT was acquired by AstraZeneca for £702m in 2006. AstraZeneca subsequently acquired MedImmune LLC, which it combined with CAT to form a global biologics division called MedImmune. CAT was often described as the 'jewel in the crown' of the British biotechnology industry and during the latter years of its existence was the subject of frequent acquisition speculation.".
• Cambridge_Antibody_Technology assets "215.98".
• Cambridge_Antibody_Technology equity "180.97".
• Cambridge_Antibody_Technology extinctionYear "2007".
• Cambridge_Antibody_Technology fate "Acquired by AstraZeneca in 2006; combined with MedImmune in 2007".
• Cambridge_Antibody_Technology foundationPlace Babraham.
• Cambridge_Antibody_Technology foundedBy David_Chiswell.
• Cambridge_Antibody_Technology foundedBy Greg_Winter.
• Cambridge_Antibody_Technology foundedBy Medical_Research_Council_(United_Kingdom).
• Cambridge_Antibody_Technology foundingYear "1989".
• Cambridge_Antibody_Technology internationally "true".
• Cambridge_Antibody_Technology keyPerson Chief_executive_officer.
• Cambridge_Antibody_Technology keyPerson David_Chiswell.
• Cambridge_Antibody_Technology location Cambridgeshire.
• Cambridge_Antibody_Technology location England.
• Cambridge_Antibody_Technology location United_Kingdom.
• Cambridge_Antibody_Technology netIncome "25.25".
• Cambridge_Antibody_Technology numberOfEmployees "300".
• Cambridge_Antibody_Technology operatingIncome "147.25".
• Cambridge_Antibody_Technology owner AstraZeneca.
• Cambridge_Antibody_Technology owningCompany AstraZeneca.
• Cambridge_Antibody_Technology product Adalimumab.
• Cambridge_Antibody_Technology product Belimumab.
• Cambridge_Antibody_Technology revenue "172.5".
• Cambridge_Antibody_Technology service Monoclonal_antibody.
• Cambridge_Antibody_Technology successor MedImmune.
• Cambridge_Antibody_Technology thumbnail Black_with_strap_v2.png?width=300.
• Cambridge_Antibody_Technology type Public_limited_company.
• Cambridge_Antibody_Technology wikiPageExternalLink IP_History.
• Cambridge_Antibody_Technology wikiPageID "23574418".
• Cambridge_Antibody_Technology wikiPageRevisionID "603943219".
• Cambridge_Antibody_Technology areaServed "Worldwide".
• Cambridge_Antibody_Technology assets "12958.8".
• Cambridge_Antibody_Technology equity "10858.2".
• Cambridge_Antibody_Technology fate "Acquired by AstraZeneca in 2006; combined with MedImmune in 2007".
• Cambridge_Antibody_Technology footnotes "*Financials for six-month period prior to acquisition by AstraZeneca were distorted by the settlement for royalties payable on Adalimumab sales".
• Cambridge_Antibody_Technology foundation "1989".
• Cambridge_Antibody_Technology founder "David Chiswell, Sir Greg Winter, Medical Research Council".
• Cambridge_Antibody_Technology hasPhotoCollection Cambridge_Antibody_Technology.
• Cambridge_Antibody_Technology industry "Biopharmaceutical".
• Cambridge_Antibody_Technology intl "Yes".
• Cambridge_Antibody_Technology keyPeople David_Chiswell.
• Cambridge_Antibody_Technology keyPeople "Peter Chambré".
• Cambridge_Antibody_Technology location "Granta Park, Cambridgeshire, England, United Kingdom".
• Cambridge_Antibody_Technology logo "200".
• Cambridge_Antibody_Technology name "Cambridge Antibody Technology Group Plc".
• Cambridge_Antibody_Technology netIncome "1515.0".
• Cambridge_Antibody_Technology numEmployees "Approximately 300".
• Cambridge_Antibody_Technology operatingIncome "8835.0".
• Cambridge_Antibody_Technology owner "AstraZeneca".
• Cambridge_Antibody_Technology products "Adalimumab, discovery of; belimumab discovery of".
• Cambridge_Antibody_Technology revenue "10350.0".
• Cambridge_Antibody_Technology services "Therapeutic monoclonal antibody discovery and development".
• Cambridge_Antibody_Technology successor MedImmune.
• Cambridge_Antibody_Technology type Public_limited_company.
• Cambridge_Antibody_Technology subject Category:1989_establishments_in_England.
• Cambridge_Antibody_Technology subject Category:AstraZeneca.
• Cambridge_Antibody_Technology subject Category:Companies_based_in_Cambridge.
• Cambridge_Antibody_Technology subject Category:Companies_established_in_1989.
• Cambridge_Antibody_Technology subject Category:Companies_formerly_listed_on_NASDAQ.
• Cambridge_Antibody_Technology subject Category:Monoclonal_antibodies.
• Cambridge_Antibody_Technology subject Category:Pharmaceutical_companies_of_England.
• Cambridge_Antibody_Technology type Abstraction100002137.
• Cambridge_Antibody_Technology type CompaniesBasedInCambridge.
• Cambridge_Antibody_Technology type CompaniesEstablishedIn1989.
• Cambridge_Antibody_Technology type CompaniesListedOnNASDAQ.
• Cambridge_Antibody_Technology type Company108058098.
• Cambridge_Antibody_Technology type DrugCompany108002578.
• Cambridge_Antibody_Technology type Group100031264.
• Cambridge_Antibody_Technology type Institution108053576.
• Cambridge_Antibody_Technology type Organization108008335.
• Cambridge_Antibody_Technology type PharmaceuticalCompaniesOfTheUnitedKingdom.
• Cambridge_Antibody_Technology type SocialGroup107950920.
• Cambridge_Antibody_Technology type YagoLegalActor.
• Cambridge_Antibody_Technology type YagoLegalActorGeo.
• Cambridge_Antibody_Technology type YagoPermanentlyLocatedEntity.
• Cambridge_Antibody_Technology type Agent.
• Cambridge_Antibody_Technology type Company.
• Cambridge_Antibody_Technology type Organisation.
• Cambridge_Antibody_Technology type Organization.
• Cambridge_Antibody_Technology type Agent.
• Cambridge_Antibody_Technology type SocialPerson.
• Cambridge_Antibody_Technology type Thing.
• Cambridge_Antibody_Technology comment "Cambridge Antibody Technology (officially Cambridge Antibody Technology Group Plc, informally CAT) was a biotechnology company headquartered in Cambridge, England, United Kingdom. Its core focus was on antibody therapeutics, primarily using phage display and ribosome display technology.Technology developed by CAT was used to create adalimumab, the first fully human antibody blockbuster drug.".
• Cambridge_Antibody_Technology label "Cambridge Antibody Technology".
• Cambridge_Antibody_Technology sameAs m.06wbqqr.
• Cambridge_Antibody_Technology sameAs Q5025351.
• Cambridge_Antibody_Technology sameAs Q5025351.
• Cambridge_Antibody_Technology sameAs Cambridge_Antibody_Technology.
• Cambridge_Antibody_Technology wasDerivedFrom Cambridge_Antibody_Technology?oldid=603943219.
• Cambridge_Antibody_Technology depiction Black_with_strap_v2.png.
• Cambridge_Antibody_Technology isPrimaryTopicOf Cambridge_Antibody_Technology.
• Cambridge_Antibody_Technology name "Cambridge Antibody Technology Group Plc".